Leerink initiated coverage of Aktis Oncology (AKTS) with an Outperform rating and $31 price target The firm is positive on the Aktis story as the company aims to expand the target space for radiopharmaceuticals, and has the potential to be first-in-class with its pipeline programs. Both AKY-1189 and AKY-2519 address targets that represent potential blockbuster opportunities. They are also both addressing targets that have some level of de-risking given advances made in the antibody-drug conjugate space, Leerink adds.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AKTS:
- Aktis Oncology initiated with a Buy at BofA
- Aktis Oncology: Differentiated Miniprotein Radiopharma Platform Underpins Buy Rating and Multi-Billion Dollar Sales Potential
- Aktis Oncology initiated with a Buy at TD Cowen
- Aktis Oncology initiated with an Overweight at JPMorgan
- Opening Day: Aktis Oncology raises $318M in 2026’s first biotech IPO